Exposure to Ebola Virus and Risk for Infection with Malaria Parasites, Rural Gabon.


Journal

Emerging infectious diseases
ISSN: 1080-6059
Titre abrégé: Emerg Infect Dis
Pays: United States
ID NLM: 9508155

Informations de publication

Date de publication:
02 2020
Historique:
pubmed: 13 12 2019
medline: 5 1 2021
entrez: 13 12 2019
Statut: ppublish

Résumé

An association between malaria and risk for death among patients with Ebola virus disease has suggested within-host interactions between Plasmodium falciparum parasites and Ebola virus. To determine whether such an interaction might also influence the probability of acquiring either infection, we used a large snapshot surveillance study from rural Gabon to test if past exposure to Ebola virus is associated with current infection with Plasmodium spp. during nonepidemic conditions. We found a strong positive association, on population and individual levels, between seropositivity for antibodies against Ebola virus and the presence of Plasmodium parasites in the blood. According to a multiple regression model accounting for other key variables, antibodies against Ebola virus emerged as the strongest individual-level risk factor for acquiring malaria. Our results suggest that within-host interactions between malaria parasites and Ebola virus may underlie epidemiologic associations.

Identifiants

pubmed: 31829919
doi: 10.3201/eid2602.181120
pmc: PMC6986822
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

229-237

Références

Science. 2015 Mar 13;347(6227):1240-2
pubmed: 25766232
Emerg Infect Dis. 2005 Mar;11(3):385-90
pubmed: 15757552
Microbes Infect. 2005 Jun;7(7-8):1005-14
pubmed: 16002313
PLoS Negl Trop Dis. 2011 Jun;5(6):e1175
pubmed: 21666792
J Infect Dis. 1999 Feb;179 Suppl 1:S102-7
pubmed: 9988172
Viruses. 2018 Oct 09;10(10):
pubmed: 30304789
Clin Infect Dis. 2016 Oct 15;63(8):1026-33
pubmed: 27531847
Asian Pac J Trop Med. 2017 Jan;10(1):6-10
pubmed: 28107867
Lancet. 2000 Jun 24;355(9222):2210-5
pubmed: 10881895
J Infect Dis. 2011 Nov;204 Suppl 3:S768-75
pubmed: 21987749
Lancet Infect Dis. 2017 May;17(5):545-552
pubmed: 28094208
N Engl J Med. 2018 Sep 27;379(13):1198-1201
pubmed: 30134126
Lancet Infect Dis. 2019 Jun;19(6):648-657
pubmed: 31000464
Int J Parasitol. 2014 Jun;44(7):437-45
pubmed: 24704058
Med Mal Infect. 2014 Dec;44(11-12):491-4
pubmed: 25391486
Lancet Infect Dis. 2017 Jun;17(6):654-660
pubmed: 28258817
N Engl J Med. 2016 Jan 7;374(1):23-32
pubmed: 26735991
Infect Genet Evol. 2014 Jul;25:52-6
pubmed: 24727548
Lancet. 2017 Feb 4;389(10068):505-518
pubmed: 28017403
Emerg Infect Dis. 2016 Mar;22(3):433-41
pubmed: 26886846
J Clin Invest. 2015 Dec;125(12):4421-8
pubmed: 26551677
Res Virol. 1989 Jul-Aug;140(4):319-31
pubmed: 2505350
Emerg Infect Dis. 2018 Dec;24(12):2228-2240
pubmed: 30307845
J Infect Dis. 1999 Feb;179 Suppl 1:S28-35
pubmed: 9988162
PLoS One. 2013;8(4):e60579
pubmed: 23577127
Clin Infect Dis. 1999 Oct;29(4):831-5
pubmed: 10589898
Emerg Infect Dis. 2019 May;25(5):911-918
pubmed: 31002071
PLoS Med. 2009 Mar 24;6(3):e1000048
pubmed: 19323591
Lancet Infect Dis. 2017 Jun;17(6):645-653
pubmed: 28256310
PLoS Negl Trop Dis. 2017 Feb 2;11(2):e0005265
pubmed: 28151955
J Clin Invest. 2015 Dec;125(12):4692-8
pubmed: 26551684
PLoS One. 2015 Jun 03;10(6):e0126933
pubmed: 26039338
PLoS Negl Trop Dis. 2011 Oct;5(10):e1329
pubmed: 22022623
Sci Rep. 2015 Aug 27;5:13476
pubmed: 26310922
Lancet Infect Dis. 2016 Jun;16(6):e82-e91
pubmed: 27020309
Lancet Infect Dis. 2015 Jul;15(7):825-32
pubmed: 25921597
Lancet. 2014 Oct 25;384(9953):1499-500
pubmed: 25390569
Lancet Infect Dis. 2015 Aug;15(8):905-12
pubmed: 25910637
PLoS One. 2010 Feb 09;5(2):e9126
pubmed: 20161740
Microbes Infect. 2000 Jan;2(1):39-44
pubmed: 10717539
Emerg Infect Dis. 2009 Jul;15(7):1136-7
pubmed: 19624943
mSphere. 2017 Aug 23;2(4):null
pubmed: 28861524
Antiviral Res. 2018 Dec;160:175-182
pubmed: 30395872
PLoS Negl Trop Dis. 2019 Jun 13;13(6):e0007428
pubmed: 31194734
Parasitol Today. 1995 Mar;11(3):105-11
pubmed: 15275362
Clin Infect Dis. 2018 Jan 6;66(1):36-44
pubmed: 29020340

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH